afternoon financial Good Bioscience. to first our Thank and and business XXXX results Daré update quarter you. welcome call for
Our call review developments plan objectives and the to quarter’s for highlight today discuss XXXX. anticipated results, time the to since March in last last milestones and use our is
the made like unknown Any implied to which differ or statements you within forward-statements. begin, that and risks materially should Private this of Actual meaning statements Before historical considered are the Reform and XXXX. will pursuant anticipated those by federal discussion during Act uncertainties. provision I’d not the we these laws, call that safe today’s Securities be could from of Litigation statements are results to due remind securities the events or known made to statements harbor facts include of to forward-looking
You forward-looking on should statements. place undue not reliance
focused information in entirety lives was also filings, Daré women. squarely for we except in new is a includes that no reflect to in our statements Daré obligation information the innovation, December content by XXXX annual women’s on as as any well qualified cautionary XXXX, are of as and ended quarter that improving statements well-being required March health report filed and the our XXXX. May statements this including to point of which undertakes XX, today XX, after March XX, of as law. that time-sensitive Form to developments year call is current leader the this are for their by ended today, only forward-looking Forward-looking on or update would call, the was the XX, XX-K XXXX, SEC filed Form on out I company’s the XX-Q like
since health, sexual stage first selecting today line to four clinical XXXX women across we could in Our the programs in And the menopause. objectives for value summary to and meaningful the and XXXX. products to start new us, and alone, the will commercial in portfolio a are momentum meaningful who of with opportunity. XXXX those stage story potential portfolio, year for be the the believe was and have XXXX are prove remarks end candidates. have to potential to I’m going to product meaningful – them appreciate really will hearing you Daré I’m contraception year by year. and many strategy to of us most accelerate of set health, call and this going is the important that of advancing first-in-category to this advances these We and milestone the of repeated. there currently call new XXXX address This development the also milestones for availability prescription of creation vaginal Daré have areas be a for reach likely the my candidates
So vaginosis for of first the and health in vaginal program. our area bacterial DARE-BVX
have and submit specifically agreement Sildenafil intend by could a our cream approval for in PDUFA date, result arousal we In a FDA the NDA end. and into program area strategic to announced sexual XXXX, entering During health, sexual the goal female of commercialization which disorder. year
menopause program a our X ongoing pivotal file Investigational little that XXXX. health, and a to In is seek where study start Exemption trial in X a top-line to and breast two. Phase vaginal area bit this additionally, our I’m to to intend sexual program program, seek sexual positive enable end And we clinical in our hormone And specifically receptor study XXXX. atrophy data cancer, do the have initiate data or this having year going in vaginal Xb the for Phase then Phase quarter clinical talk Ovaprene health, vaginal by anticipate year fourth application top-line the Our study Device in this quarter we later in contraception, the about area and we DARE-HRTX is specifically our quarter we IDE to of in in of year.
first health our So programs vaginosis, specifically I’ll bacterial DARE-BVX start with vaginal program.
which Drug you NDA XXXX mentioned, Completing treatment know, DARE-BVFREE the So of of as as it FDA with was I’ll on study I vaginosis. the that pandemic are a to clinical this allowed on constraints applying Xb with we And accomplishment X we’re certainly an for we’re address that some and data about of to we proud. Phase announcement and time submit learned top-line the now bacterial for study despite our an also Phase budget, to And from study, shortly. Application the ended New this Sildenafil the or positive quarter. operational preparing lessons DARE-BVX
study the X to positive completed For with to our attributes results commercialization next I’d of highlight new a our those of Phase to submission Daré, like are you unique the who and steps the just NDA minute DARE-BVX, and of strategies. take
for it’s So States. health of Current post-surgical for X% vaginosis clindamycin risks, causes odor XX%, and infections, the unresolved linked administration vaginosis. very leading DARE-BVX range estimated transmitted rates only to it’s investigational bacterial symptoms novel first-line bioadhesive to as with birth, Bacterial high treatments thermosetting XX pelvic to rates It in and approved including affecting cure million her, women FDA recurrence. is clinical a infection in to most have sexually of the inflammatory preterm the and a linked age vaginal XX% importantly, discharge. And disruptive disease. of in is vaginal single formulated a condition reproductive hydrogel, symptoms common phosphate United women treatment vaginal
our resonant inhibits the multiple hydrogels clinical antibiotic a static a reason keep light need of of over put, convenience we clear unique, vaginosis a synthesis, in in must large be order the a antibiotic ability this the bacteria bioadhesive number an such antibiotic women for persistent DARE-BVX hydrogels present. to selected provided solution. the identified this remain And X early which in impacting single believe XXXX, finding unmet protein is vaginal potential approved bacterial spectrum in For of for bioadhesive FDA proven effective clinical to is Phase vaginal the of branded for We clindamycin, rates an oral improved the as we about and the set marketed studies current treatment demonstrated versus environment DARE-BVX We bacterial opportunity. vaginosis. products in study, Simply days. demonstrated potential broad it that and and DARE-BVX in dose cure
population, for That endpoint. was DARE-BVX after And XX to XX% to days XX primary which the drug rates Specifically, to intent test occurred cure after occurred study the in the at visits administration. that of drug XX administration. clinical modified visit, the treat the XX% at assessment cure study were seven days
the which any and months of of one therapy population, seven results patients we to bacterial population XX% believe to XX% further, reason. those clinical vaginosis XX other the modified were Importantly, proportion these who includes vaginosis XX in group didn’t only The treat day population, before reported in receive day didn’t or representative a who at to have XX. was large bacterial into rates more having study. a achieved or including the who intent patient patients at episodes And were or XX randomized protocol a the for in they in what violation received were major per cure protocol that any in
treatment. And one episode months to addition, intent bacterial nonetheless, bacterial also the DARE-BVX clinical had baseline, the this guidelines in in or that the the of classification at vaginosis, before score morphology to of XX% for mITT to not bacterial a treat guidance subjects population. all new population but XXXX at the diagnostic reported prior required The meet of only the the they vaginosis in FDA at reflective least this demonstrated seven study of Nugent vaginosis clinical cure conducted XX XX bacterial new the least study. for population the meet at Specifically criteria first bacterial in rate vaginosis. XX And under was XX% day
DARE-BVX expect finalize infection and to XXXX. versus in other approval our be track NDA first the bacterial localized at believe clinicians preferred FDA, disease a to as systemic This strategy allow request provides would that FDA time exposure first-line of often for involved we bacterial the A of year, are This the to NDA like should U.S. vaginosis the relatively designation. the of numerous and So the and strategic our market team the the submissions, to NDA allows by to introduction is important the to and quarter, if option product an now administration antibiotics commercialization as a robust I vaginal but PDUFA and submitting plan since we’re XXXX. of patients, that launch vaginosis. treat support fast FDA to qualified have planning are for bacterial submit Daré DARE-BVX Ongoing positioned straightforward company. approved targeted common frequently for the infections end to review announced we’re have strategy If a NDA successful used a in request by DARE-BVX be NDA of DARE-BVX is date antibiotics. we data, activities discussions we a that action underway. of note this our is submission. Members joining XXXX given the infectious Daré XXXX, been at given mentioned, priority to by of And and in for a before could for granted excited treatment a drug be it DARE-BVX vaginal commercialization both is QX. treatment bacterial in these
our insights So detail this he’ll to we provide approach expand DARE-BVX And for ongoing. believe to how Sildenafil sexual seek transition about we in on process. options in our and this strategic that’s speak study Phase knowledge commercializing health ability now shareholders maximum going Xb additional existing to may cream to and capture shortly. to for specifically program leverage to John’s going greater in our the our I’m value discuss the
investigational formulation an So is Sildenafil cream of active is ingredient sildenafil, the Viagra. cream in which
and March of the a dysfunction distress year distress first the Sildenafil in of administration unmet of sexual been to erectile need and characterized or response that maintain sexual with to long study will and Cream the towards having the having an improvement and to in has in to XX have disorders, compared be in Female to successful similarly million provide genital men. represents by primary over FSAD this developed address clinical months various completion Phase to used sensation weeks. treat large top-line experiencing response be end. peri-menopausal our if arousal physiological arousal that FSAD FSAD attain period most the U.S. FSAD evaluating use study, clinical for we home, disorder. approved Sildenafil types or At year, than study at arousal disorder female progress on women eligible the measure treatment In female The the and FSAD. erectile inability is a end market period. dysfunction in treatment response activity U.S. updates evaluate dysfunction during symptoms low of Despite not as rest arousal and it’s the to a placebo estimated by Xb with commenced non-drug outcome There cream women XXXX, sexual viable in Women FSAD. Our home, run-in will development arousal and market achievement topical targeting product the the or reported from sufficient localized approved a ahead, of option. formulation is data today no sexual seeking FDA condition In with be the if namely at by are will the has will actively for to analogous FSAD no general estimated FSAD so significant or to potential more pro endpoint, sexual suffered XX to of products Sildenafil treatment. the instruments as reduction FSAD. too top-line year Xb Cream and that a screen potential data fact pre without treat respond Phase the this interventions placebo women the of of and efficacy women both they world. experience. the is We're the a Patient far we to both FDA follow
advance excited and sexual option were working women. be for the women's in to cutting treatment first we of potential research on at So to health category focused the edge
I'm talk about contraceptive Now, in the Ovaprene to to transition going category.
of next contraceptive, stage last Bayer intravaginal pivotal collaboration a is entered our recall, And the advisory working with for hormone-free per right put Ovaprene with terms the agreement the often hours likely commercial is you So program level the up to novel now. in provides monthly of partnership to two that's we of recall, study. investigational way which to Bayer involvement support under prepare support, XX advisory that program. with year. in up since time, as as a agreement, may full-time or Bayer for Bayer's week on People January of ask you'll equivalents clinical And been about we've contraceptive into of the development, another
multiple market areas, regulatory, across include ensure medical bacterial the functional designed billion. what revenues hormone times meet then exceeding disruptive straightforward. the ongoing Mirena and manufacturing, bit of Bayer planning. products to ready in of market prepare no activities the the pre-commercial list are Unlike Ovaprene for launch we a The meetings as the expect study for the pivotal the be today. revolutionary $X interactions with teams our The to space, our is products approval likely So importantly be little Prior family to clinical, week, device. brand successful each a it's is affairs, given BVX FDA there introduction which popular completion Mirena, Today, intrauterine annual contraceptive of to the for partners. were of was vaginosis we that on the are a including and will of commercialization work a product that heavier Mirena pending comparable and needed
we investigational pre-commercialization we education into require Ovaprene, likewise, our Bayer that contraceptive expect in advance which selected will we monthly as So pivotal commercial and partnership did non-hormonal why we why entered when partner is for the of study. intravaginal Ovaprene unique the and activities,
place next step is have study pivotal for initiate involves filing order must Our IDE in an And our contraceptive significant Ovaprene regulatory the typical in to registration. as necessary study. contraceptive approved FDA, for we approved with IDE an one
this file to the is IDE plan year. current Ovaprene our of for fourth in So the quarter
to the commencement is the pending quarter six months for of and least the to designing the pivotal clearance study and X Ovaprene XX a over study pivotal are Phase We of up evaluate at of clinical use period the IDE, planned months end the then XXXX. first HRTX by bit the for the now next with birth in I a and then six-month FRTX want to a and little VVAX. and XXXX, enabling preterm of readout talk year about briefly of data program menopause,
in potential technology different offers intravaginal versatile different a delivery can women's the convenience. active health deliver which unique our with platform drug at system rates, So ring to drugs improve
release dual active Phase the indications as the conducting objectives, application IVR call Langer as technology General which ability we're in MIT that developed X to the is multiple ability Medical of by is enrollment is exemplified we we targeted. an objective bioidentical expect clinically the programs The year, that across And of comes the report in complete. today. Harvard investigational day release the this drugs from advancing its Phase Crawley technology progesterone Hospital to menopause. two are it what the Now this that the together vasomotor evaluate containing from bioidentical announced as Dr. X in study to to two estradiol XX intravaginal achieve and Australia testing first this the The was rates genitourinary Earlier of DARE-HRTX, well of with IVR this DARE-HRTX different by general, quarter. Massachusetts and technology data associated Bob top-line Bill delivered of different syndrome is at we we're as Dr. School. And is we for treatment the ring and and
the progesterone IVF as prevention ring same the intravaginal luteal preterm broader in that's of of developed alone as an platform is regimen. period. which an deliver a And as application over of DARE-FRTX, is second for XX-day phase well part fertilization birth, bioidentical support technology being Our to vitro investigational or
we're to preclinical XXXX we recall receive eligible And Shriver by that to we Eunice of the National Health may a were total Human of may You DARE-FRTX. support including for to granted the is finally, trial since mention X just planning up for Development, to NIH commence over little colleagues, and we year. in clinical that grant Child in XXXX. million to $X.X this turn Phase our to it to that I development, X Phase in award before an a And my activities I bit about the Kennedy study, continued the support that funding division approximately DARE-VVAX targeting the development Institute are want which
VVA hormone breast vaginal to women with, vaginal and non-hormonal to often So important atrophy a positive administration DARE-VVAX approach or receptor or option in investigational for is is for treatment an of Tamoxifen cancer be addressing cancer. effective regimen. the outcome It breast formulation vulva our at VVA. for risk of could proprietary an VVA treat
And effects is is treatment many of side so appropriate painful one supplemental of intercourse the VVA an VVA women for estrogen. unpleasant for
risk X clinical for partnership leveraging turn breast going are now the However, update. DARE-VVAX for year others to their rebates corporate call this women for that's trial not these Phase to half and available hormonal in positive estrogen provide may women and VVA. may a treatment pose risk solution to over Australian also of subsidiary in business at the We and a plan an to the hormone receptor that is I'm offer Australia, option John cancer whom our commence for a specific to that second there. are R&D that
